Researchers at the Max Planck Institute for Molecular Genetics have developed a novel synthetic micropeptide termed the ...

Figure 3. (A) Flow cytometry measurements of an MGMT-GFP fusion upon LomG (5 μM) treatment in cells labeled for the cell cycle phase show no cell cycle dependency in the degradation. (B) HEK293T cells ...

The state has pledged $10M for local companies and to match grants supporting these proteins, and another $115M for an infrastructure programme to support job growth in key tech sectors, including ...

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in ...

PD-1/IL-2 α-bias bispecific antibody fusion protein IBI363 in patients with immunotherapy resistant advanced non-small cell lung cancer: results from a Phase 1 study. Updated data on IBI363 ...

PD-1/IL-2 α-bias bispecific antibody fusion protein IBI363 monotherapy and combined with bevacizumab in participants with advanced colorectal cancer: results from Phase 1 studies Two Phase 1 studies ...

Here we report the first example of intermolecular communication between two proteins coencapsulated within the capsid architecture of the bacteriophage P22. Using a genetically engineered ...

NAGLU–IGFII fusion protein (to be subsequently called “enzyme” in the text and “ENZ” in figures) was administered in artificial cerebrospinal fluid (“vehicle” in the text, “VEH” in figures) to the ...

After a decline in alternative protein investments in 2024, funding further fell by 28% in Q1 2025 compared to the same period a year ago. Analysts blame AI, high costs, and low sales. There’s no ...